BIIB241129P220000
- 0.00
- 0.000.00%
Biogen Newsroom
Are Biogen Inc.'s (NASDAQ:BIIB) Mixed Financials Driving The Negative Sentiment?
Anavex Gains After Seeking EU Marketing Nod for Alzheimer's Drug
Jefferies Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $250
Jefferies Remains a Buy on Biogen (BIIB)
Are Wall Street Analysts Predicting Biogen Stock Will Climb or Sink?
Trump Picks Surgeon Makary to Head FDA, Rep. Dave Weldon to Lead CDC
Goldman Sachs: Biogen Inc. (BIIB) Is A Top Growth Investor Stock
Biogen Price Target Lowered to $207 From $251 at Mizuho
Optimism Over Global Healthcare Sector Rises: Jefferies
Biogen Is Maintained at Outperform by Mizuho
Mizuho Securities Maintains Biogen(BIIB.US) With Buy Rating, Announces Target Price $207
European Commission Approves Samsung Bioepis, Biogen's Biosimilar Opuviz
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
Mizuho Securities Adjusts Price Target on Biogen to $207 From $251
Biogen Inc. (BIIB): Among the Best Genomics Stocks to Buy Right Now
Lupus Therapeutics Statement on Phase 3 PHOENYCS GO Positive Data in Moderate-To-Severe Systemic Lupus
UCB And Biogen Present Phase 3 Data On Dapirolizumab Pegol, Showing Significant Lupus Activity Reduction
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
Biogen to Participate in the 7th Annual Evercore HealthCONx Conference
Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026